Literature DB >> 1825919

Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.

V Hug1, S Kau, G N Hortobagyi, L Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1825919      PMCID： PMC1971863          DOI： 10.1038/bjc.1991.105

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  9 in total

1.  Cushing syndrome and medroxyprogesterone acetate.

Authors:  J E Donckier; L A Michel; M Buysschaert
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

2.  The Cushing syndrome induced by medroxyprogesterone acetate.

Authors:  K Siminoski; P Goss; D J Drucker
Journal:  Ann Intern Med       Date:  1989-11-01       Impact factor: 25.391

3.  Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.

Authors:  F Pannuti; A Longhi; A Martoni; E Piana; M Baroni
Journal:  Chemioterapia       Date:  1987-12

4.  [Estrogen-induced proteins secreted by MCF7 human breast cancer cells stimulate their proliferation].

Authors:  F Vignon; D Derocq; M Chambon; H Rochefort
Journal:  C R Seances Acad Sci III       Date:  1983-01-24

5.  Adrenal steroids as parameters of the bioavailability of MA and MPA.

Authors:  P H Willemse; L D Dikkeschei; T Tjabbes; H van Veelen; D T Sleijfer
Journal:  Eur J Cancer       Date:  1990-03       Impact factor: 9.162

6.  Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate.

Authors:  H C Blossey; H E Wander; J Koebberling; G A Nagel
Journal:  Cancer       Date:  1984-09-15       Impact factor: 6.860

7.  Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; W J Sluiter; H Doorenbos
Journal:  Cancer Treat Rep       Date:  1985-09

8.  Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; E van der Ploeg; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Sequential cyclic combined hormonal therapy for metastatic breast cancer.

Authors:  G N Hortobagyi; V Hug; A U Buzdar; S W Kau; F A Holmes; H A Fritsche
Journal:  Cancer       Date:  1989-09-01       Impact factor: 6.860
  9 in total
  1 in total

1.  Cushing's syndrome with adrenal suppression and masked hyperandrogenism by high-dose medroxyprogesterone acetate for treatment of endometrial cancer in a young woman with polycystic ovarian syndrome.

Authors:  Yoorim Seo; Eun Gyo Jeong; Eun Sook Kim
Journal:  Endocrine       Date:  2015-08-23       Impact factor: 3.633
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.